AVEO Pharmaceuticals, Inc. (AVEO)
(Delayed Data from NSDQ)
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AVEO 0.94 +0.04(4.01%)
Will AVEO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AVEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVEO
HCA Healthcare (HCA) Rises 43% in 6 Months: More Room to Run?
GSK Signs Deal to Develop Antibodies for Treating Cancer
AVEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences